Week In Review: Management Offers $3.5 Billion To Privatize Mindray Medical

Mindray Medical, the Shenzhen medical device company, was put in play by a $3.5 billion privatization offer made by its three top executives; Luye Pharma of Shandong terminated its $1 billion agreement to buy Beijing Jialin Pharma, citing "prudence" as a reason; Madrid-based Faes Farma set up a JV with Eddingpharm of Hong Kong to market Faes' products in China; WuXi AppTec supplied its NextCODE genomic tools to a consortium of research universities and institutes led by Fudan University; the Chinese Academy of Sciences broke ground on a $323 million genomics R&D Center in Changzhou; China ended the official caps on most drug prices, but provincial authorities are putting pressure on prices of big pharma drugs; AstraZeneca and Hutchison China MediTech announced positive data from a Phase Ib trial of a novel cancer drug that AstraZeneca in-licensed from Chi-Med; and CASI Pharma of the US and China filed for CFDA approval to begin a fourth China Phase II clinical trial of its lead drug candidate.

Help employers find you! Check out all the jobs and post your resume.